ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure

McMurray, John J., V*; Wheeler, David C.; Stefansson, Bergur, V; Jongs, Niels; Postmus, Douwe; Correa-Rotter, Ricardo; Chertow, Glenn M.; Hou, Fan Fan; Rossing, Peter; Sjostrom, C. David; Solomon, Scott D.; Toto, Robert D.; Langkilde, Anna Maria; Heerspink, Hiddo J. L.南方医科大学
JACC-Heart Failure2021-11DOI: 10.1016/j.jchf.2021.06.017
41被引8阅读
引用收藏
分享

摘要

OBJECTIVES The purpose of this paper was to investigate the effects of dapagliflozin in chronic kidney disease (CKD) patients, with and without heart failure (HF). @@@ BACKGROUND Patients with CKD, with and without type 2 diabetes, were enrolled in the DAPA-CKD (Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease) trial. Some patients had HF at baseline. @@@ METHODS A total of 4,304 participants were randomized to dapagliflozin 10 mg daily or placebo. The primary composite endpoint was >= 50% decline in estimated glomerular filtration rate, end-stage kidney disease, or kidney/cardiovascular death. Secondary endpoints were a kidney composite (primary endpoint minus cardiovascular death), the composite of cardiovascular death/HF hospitalization, and all-cause death. Analysis of outcomes according to HF history was prespecified. @@@ RESULTS HF patients (n = 468; 11%) were older and had more coronary disease, atrial fibrillation, and type 2 diabetes. Mean estimated glomerular filtration rate was similar in patients with and without HF. Rates of HF hospitalization/cardiovascular death and death from any cause were higher in HF patients, but the secondary kidney failure outcome occurred at the same rate in people with and without HF. Dapagliflozin reduced the risk of the primary outcome equally in patients with HF (HR: 0.58 [95% CI: 0.37-0.91]) and without HF (HR: 0.62 [95% CI: 0.51-0.75]) (P interaction = 0.59). The proportional risk-reductions were similar in patients with and without HF for the cardiovascular death/HF hospitalization composite (HR: 0.68 [95% CI: 0.44-1.05] vs HR: 0.70 [95% CI: 0.51-0.97], respectively; P interaction = 0.90), and all-cause death (HR: 0.56 [95% CI: 0.34-0.93] vs HR: 0.73 [95% CI: 0.54-0.97], respectively; P interaction = 0.39), although absolute risk reductions were larger in HF patients. Adverse event rates were low and did not differ among patients with or without HF. @@@ CONCLUSIONS Dapagliflozin reduced the risk of kidney failure and cardiovascular death/HF hospitalization and prolonged survival in CKD patients with or without type 2 diabetes, independently of history of HF.

学科与关键词

关键词
cardiovascular diseasechronic kidney diseasedapagliflozinheart failureSGLT2 inhibitor
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
JACC-Heart Failure
发表日期
2021-11
卷期
第 9 卷, 第 11 期
页码
807-820
DOI
10.1016/j.jchf.2021.06.017
语言
ENGLISH
期刊收录
NSL
期刊等级
1区
成果收录
SCIE
资助标注
AstraZeneca; British Heart Foundation Centre of Research Excellence [RE/18/6/34217]; Alnylam; Theracos; Abbott; Sun Pharmaceuticals; Amgen; Mundipharma, Medscape; Pharmacosmos, Reata; GlaxoSmithKline; Boehringer Ingelheim; Novo Nordisk; NIDDK; DiaMedica; Durect; Akebia, Sanifit; Angion; Bayer; Mundi-pharma; Actelion; Ionis; Lone Star Heart, Mesoblast; National Institutes of Health/National Heart, Lung, and Blood Institute; NovoNordisk; Arena; Lilly; Merck; Sanofi-Pasteur; Otsuka; Mundi Pharma; Mitsubishi Tanabe; Abbvie; Janssen

作者

  • M

    McMurray, John J., V (通讯) (第一作者)

  • W

    Wheeler, David C.

查看全部 14 位作者收起作者
  • S

    Stefansson, Bergur, V

  • J

    Jongs, Niels

  • P

    Postmus, Douwe

  • C

    Correa-Rotter, Ricardo

  • C

    Chertow, Glenn M.

  • H

    Hou, Fan Fan

    southern med univ

  • R

    Rossing, Peter

  • S

    Sjostrom, C. David

  • S

    Solomon, Scott D.

  • T

    Toto, Robert D.

  • L

    Langkilde, Anna Maria

  • H

    Heerspink, Hiddo J. L.

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417